Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04887870
Title Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study
Recruitment Enrolling by invitation
Gender both
Phase Phase II
Variant Requirements No
Sponsors Mirati Therapeutics Inc.
Indications

Advanced Solid Tumor

Therapies

Ipilimumab + Sitravatinib

Nivolumab + Sitravatinib

Enfortumab vedotin-ejfv + Sitravatinib

Pembrolizumab + Sitravatinib

Sitravatinib

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.